UT Austin licenses unique delivery technique for AMD

Patient compliance has long been a problem associated with treatment of wet type age-related macular degeneration (AMD). Current treatment is simply not very pleasant and may require many painful injections over six months. A longtime goal among pharmaceutical companies is to develop something easier for drug delivery to the back of the eye. The University of Texas at Austin is licensing what it says is a unique solution for wet type AMD drug delivery. The treatment involves a one-time implantation of a carrier system for the drug. Then, each time the patient needs medication, the doctor can operate a laser beam to release it in measurable doses. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.